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Abstract
Introduction: It is pertinent to evaluate the impact of vaccination against human 
 papillomavirus (HPV) in real life. The aim of the study was to evaluate the real-life 
 impact of HPV vaccination in the first birth cohort of Danish women offered free 
HPV vaccination as girls and invited to screening at the age of 23 years.
Material and methods: Women born in 1993 were offered free HPV vaccination at 
the age of 15 years but women born in 1983 have never been offered free HPV 
vaccination. We followed these two birth cohorts for 10 years from the age of 15 
to after their first invitation to screening, and compared the risk of high-grade cervi-
cal intraepithelial neoplasia (CIN). Data were obtained from Danish national health 
registers.
Results: Vaccination coverage was 91% in the 1993 birth cohort and <0.1% in the 
1983 cohort. Screening coverage was close to 80% in both cohorts. CIN2+ was de-
tected in 4% of the 15 748 screened women born in 1983 and in 3% of the 19 951 
screened women born in 1993. The risk of high-grade CIN was reduced by about 30% 
in the 1993 cohort compared with the 1983 cohort; for CIN2+ relative risk 0.74 (95% 
CI 0.66-0.82) and for CIN3+ relative risk 0.68 (95% CI 0.58-0.79).
Conclusions: This study investigated the real-life impact of quadrivalent HPV vac-
cination by comparing a cohort of women offered HPV vaccination with a cohort 
of women not offered HPV vaccination. The observed decrease in the detection of 
high-grade cervical lesions following HPV vaccination is in line with results from the 
randomized trials and has important implications for future cervical screening of HPV 
vaccinated cohorts.
K E Y W O R D S
cervical intraepithelial neoplasia, early detection of cancer, human papillomavirus, prevention 
and control, vaccination
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1  | INTRODUC TION
Human papillomavirus (HPV) vaccination was introduced 
 following randomized trials.1,2 Young women recruited to the tri-
als had no history of genital warts or abnormal cervical cytology, 
and a lifetime maximum of four sexual partners.1,2 To compare, 
half of young Danish women reported a lifetime number of least 
five sexual partners.3 As a result of these restrictions in the trial 
populations, and because HPV vaccination is now a public health 
initiative for the population in general, it is pertinent to deter-
mine the real-life effectiveness of HPV vaccination. This poses 
two challenges. First, in a population-based program uptake/
not-uptake of HPV vaccination is not randomly allocated. Second, 
high-grade cervical intraepithelial neoplasia (CIN) does not cause 
symptoms, and is therefore, detected only in screened or oth-
erwise examined women. We designed our study to take these 
factors into account.
In 2009, Denmark started recommending routine HPV vac-
cination for 12-year-old girls. From October 2008, girls aged 
13-15 years and born in 1993-1995 were offered free vaccination 
with the quadrivalent HPV vaccine.4 The quadrivalent HPV vac-
cine was used until February 2016, after which the bivalent HPV 
vaccine was used, until it was replaced by the nonavalent HPV vac-
cine in 2017.5
We previously reported the impact of HPV vaccination on cy-
tology outcome at first screening, and found a 40% reduction in the 
prevalence of high-grade squamous intraepithelial lesions (HSIL).6 
Here we report on the impact of HPV vaccination on the prevalence 
of high-grade CIN.
Previous observational studies on the effect of quadrivalent HPV 
vaccination compared vaccinated and unvaccinated women from the 
same birth cohorts.7 To the best of our knowledge, ours is the first 
study to determine the real-life impact of quadrivalent HPV vaccina-
tion by comparing entire populations from well-defined areas. The 
objective of this population-based cohort study was to evaluate the 
effect of HPV vaccination on prevalence of histologically confirmed 
high-grade CIN.
2  | MATERIAL AND METHODS
Women born in 1993 were defined as exposed to HPV vaccination, 
because they were offered free HPV vaccination at age 15 years in 
2008. Women born in 1983 were defined as unexposed, because 
they had never been offered free HPV vaccination. Women born 
between 1985 and 1992 were targeted by a catch-up program 
in 2012/13 and could consequently not be used as comparison 
cohort.8
Women born in 1983 and 1993 were identified from the Danish 
Civil Registration System with their personal identification number 
allowing for linkage with other register data. A closed cohort was 
formed of women born in 1993 present in Denmark all the time 
from 1 January 2009 (time of offer of HPV vaccination) until end of 
follow up of screening outcomes in 31 December 2018. Similarly, 
a closed cohort was formed of women born in 1983 present from 
1 January 1999 to 31 December 2008. The closed cohorts were 
followed for 10 years from age 15 to age 25 years (Figure 1). We 
excluded Copenhagen County before 2005 and 2015 because of 
incomplete pathology data. Design and analysis were in accor-
dance with our previous study of screening cytology in the same 
populations.6
Primary outcome was CIN grade two or worse (CIN2+) during 
follow up. The National Register of Pathology contains all pathol-
ogy diagnoses in Denmark, and uses the Danish Systematized 
Nomenclature of Medicine (SNOMED). The Bethesda classification 
was used from 2007, and the CIN nomenclature from 2012.9,10 All 
M-codes (morphology) were adapted to fit the Bethesda and CIN 
Key message
This study examined the real-life impact of HPV vaccina-
tion on cervical lesions by comparing entire populations 
from well-defined areas. The risk of severe cervical lesions 
was reduced by 30% after HPV vaccination.
F I G U R E  1   Lexis diagram of studied 
cohorts. Time of occurrence of worst 
diagnosis during follow up shown by 
colors
1292  |     THAMSBORG eT Al.
classifications.11 Unclassifiable codes were reviewed to ensure 
that no relevant diagnosis was missed. T-codes (topography) were 
used to distinguish between cervical histology and cytology (see 
Supplementary material, Table S1). For practical purposes, atypical 
glandular cells were included in the atypical squamous cells of un-
determined significance (ASCUS) category. Atypical squamous cells 
cannot exclude HSIL and adenocarcinoma in situ were included in 
the HSIL category.
We acquired individual HPV vaccination data from the 
National Health Services Register for vaccines given free as part 
of the childhood immunization program, and from the Prescription 
Register for the limited number of self-paid vaccines purchased 
before the start of the free program (see Supplementary mate-
rial, Table S1). HPV vaccination status was defined as at least 
one dose, and age at vaccination was determined at first dose, 
regardless of register. We used population data on education as 
recorded in national statistics (statistikbanken.dk, HFUDD20, ac-
cessed 21 August 2019), data on smoking from school health sur-
veys,12,13 and data on sexual behavior from questionnaire-based 
studies.3,14-16
2.1 | Cervical screening in Denmark
In Denmark, women are invited to cervical screening from age 
23 years every third year, from age 50 to 59 years every fifth year, 
and at age 60-64 to a check-out test. In the birth cohorts studied 
here, women with HSIL or other severe diagnoses were referred 
to a gynecologist, but women with ASCUS or low-grade squamous 
intraepithelial lesions (LSIL) were typically recommended repeated 
sampling after 3-6 months and referred to a gynecologist if still ab-
normal.17 HPV mRNA triage of ASCUS/LSIL was used for a subgroup 
of women born in 1993.9 In one of the five Danish regions, conver-
sion from conventional cytology to liquid-based cytology started in 
2002 and spread gradually to become nationwide in 2015, with most 
pathology departments using SurePath.18-20
2.2 | Statistical analyses
The closed cohorts were observed for 10 years from age 15 to 
25 years. We tabulated regional distribution at study start, screen-
ing, and HPV-vaccination coverage.
Screening outcome was defined as worst diagnosis. We ap-
plied one hierarchy of M codes in descending order. First came 
women with at least one histology diagnosis, the hierarchy was 
cervical intraepithelial neoplasia grade 3 and above (CIN3+), CIN2, 
CIN1, negative for intraepithelial lesion or malignancy (NILM) and 
unsatisfactory, or other. Then came women without a histology 
diagnosis but with at least one cytology diagnosis, the hierarchy 
was HSIL, LSIL, ASCUS, NILM, and unsatisfactory or other. The 
number of women without histology but with at least one abnor-
mal cytology visualize women awaiting further examination. In 
a sub-analysis, we stratified results for the 1993 birth cohort by 
vaccination status.
We calculated mean age at events and prevalence proportions 
with number of women screened, defined as women with a cervi-
cal histology and/or cytology registered in the National Register 
of Pathology, as denominator. As CIN does not give symptoms, 
only screened women can receive diagnosis. This means that 
screened women can only contribute to the numerator, therefore 
we used the same population as denominator. Relative risks (RR) 
and corresponding 95% CI were obtained from a multinomial lo-
gistic regression model (a generalized logit model; that is, a logit 
model with multiple responses). We compared the corresponding 
probabilities of each outcome in the two populations. RR here cor-
responded to prevalence ratios. Chi-squared test for homogeneity 
was used to calculate P-values. The significance level was set to 
0.05. SAS statistical software v. 9.4 was used, together with the 
macros NLMeaNs v. 1.04 and NLestiMate v. 1.51 to estimate the RR 
from the logistic regression. Plots were made in R v. 3.5.1, using 
the ggplot2 package.
2.3 | Ethical approval
The study was approved by the Danish Data Inspection Agency 19 
February 2016 (SUND-2016-22). According to Danish legislation, 
ethical approval is not required for register-based research.
TA B L E  1   Population characteristics; closed cohorts of Danish 
women born in 1983 and 1993
Characteristics
1983 cohort
N (%)
1993 cohort
N (%)
Number of women 
included
19 629 26 215
Region of residence at start of follow up
Capital Region 2968 (15.1) 4342 (16.6)
Zealand 3389 (17.3) 4509 (17.2)
Southern Denmark 5305 (27.0) 6889 (26.3)
Central Denmark 5336 (27.2) 7061 (26.9)
Northern Denmark 2631 (13.4) 3414 (13.0)
High school examinationa  51% 59%
Age of sexual debutb  16 years 16 years
Daily smoking at age 
15 years12,13
21% 10%
Screening coverage at 
end of follow up
15 748 (80.2) 19 951 (76.1)
HPV-vaccination 
coverage/cohortc 
(<0.1%) 23 968 (91.4)
HPV-vaccination 
coverage/screenedc 
(<0.1%) 18 612 (93.3)
aStatistikbanken.dk, HFUDD20, accessed 21 August 2019. 
bMedian age at sexual debut reported for women born 1959–
19873;1959–198614; and 1985–1994.15 
cVaccination coverage at 31 December 2006/2016. 
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3  | RESULTS
The closed cohorts included 19 629 women born in 1983 and 
26 215 women born in 1993 (Table 1, see Supplementary material, 
Figure S1). The cohorts had similar regional distributions, but with 
the large numbers studied the difference was statistically signifi-
cant (P = .001). The proportion of women who had at least a high 
school examination was slightly higher in the 1993 birth cohort—51% 
and 59%, respectively (statistikbanken.dk, HFUDD20, accessed 21 
August 2019); median age of sexual debut was 16 years in both co-
horts;3,14,15 but the proportion of women with early sexual debut 
(≤14 years) seemed to have increased from 14.3% (95% CI 13.4%-
15.1%) to 18.4% (95% CI 17.1%-19.7%).16 The percentage of women 
aged 18-24 years with >10 sexual partners increased from 14.3% 
(95% CI 13.4%-15.2%) in a 2005 survey to 17.8% (95% CI 16.7%-
19.0%) in a 2012 survey.16 The proportion of daily smokers at age 
15 years decreased from 21% to 10%.12,13 Cervical screening cover-
age was high; 80% for those born in 1983, and 76% for those born 
in 1993; a small difference, but statistically significant with the large 
numbers (P < .001).
As expected, HPV-vaccination coverage varied from <0.1% 
in the 1983 cohort to 91% in the 1993 cohort; and from <0.1% to 
93% in the screened parts of these cohorts. In the 1993 cohort, 
80% of women were vaccinated at the age of ≤15 years, and 
only 2.3% were vaccinated when older than 16 years; 84% were 
fully vaccinated with three doses, while 4% had one dose only; 
and only four women were vaccinated with the bivalent HPV 
vaccine.
In the 1983 cohort, 6.4% of all women had at least one histol-
ogy diagnosis, but this was the case for 7.8% in the 1993 cohort 
(P < .001). Among screened women, the proportions were 8.0% 
and 10.2%, respectively (RR 1.28; 95% CI 1.19-1.36) (Table 2). In 
screened women, the risk of CIN2+ in the 1993 cohort was 26% 
lower than that in the 1983 cohort (RR 0.74; 95% CI 0.66-0.82). For 
CIN3+ a similar pattern was seen (RR 0.68; 95% CI 0.58-0.79). The 
fact that slightly more screened women in the 1993 cohort than in 
the 1983 cohort had undergone biopsy, showed up in a larger risk 
of normal and low-grade diagnoses; for CIN1 with an RR 1.23 (95% 
CI 1.05-1.40), and for NILM with more than a doubled risk (RR 2.37; 
95% CI 2.08-2.67) (Figure 2).
In the 1983 cohort, 6.7% of screened women had abnormal cy-
tology and awaited further diagnostics, but this proportion had de-
creased to 4.6% in the 1993 cohort (RR 0.69; 95% CI 0.63-0.75). This 
decrease was seen primarily for HSIL with an RR of 0.18 (95% CI 
0.06-0.31) (Table 2). Age distribution at worst diagnosis was equal 
for the cohorts with mean age of 23.1 years.
1983 cohort
N = 15 748
1993 cohort
N = 19 951 1993 vs 1983
N (%) N (%) RR (95% Cl)
Any histology 1262 (8.0) 2042 (10.2) 1.28 (1.19-1.36)
Worst diagnosis
CIN2+ 628 (4.0) 590 (3.0) 0.74 (0.66-0.82)
CIN3+ 361 (2.3) 313 (1.6) 0.68 (0.58-0.79)
CIN2 267 (1.7) 277 (1.4) 0.82 (0.68-0.96)
CIN1 296 (1.9) 460 (2.3) 1.23 (1.05-1.40)
NILM histology 320 (2.0) 962 (4.8) 2.37 (2.08-2.67)
Unsatisfactory/other 
histology
18 (0.1) 30 (0.2) 1.30 (0.55-2.08)
Cytology only 14 486 (92.0) 17 909 (89.8) 0.97 (0.97-0.98)
Worst diagnosis
HSIL 47 (0.3) 11 (0.1) 0.18 (0.06-0.31)
LSIL 566 (3.6) 397 (2.0) 0.55 (0.48-0.62)
ASCUS 437 (2.8) 506 (2.5) 0.91 (0.80-1.03)
Any abnormal 1050 (6.7) 914 (4.6) 0.69 (0.63-0.75)
NILM cytology 13 297 (84.4) 16 965 (85.0) 1.01 (1.00-1.02)
Unsatisfactory/Other 
cytology
139 (0.9) 30 (0.2) 0.17 (0.10-0.24)
Abbreviations: ASCUS, atypical squamous cells of undetermined significance (incl. atypical 
glandular cells); CIN2+, cervical intraepithelial neoplasia grade 2 and above; CIN3+, cervical 
intraepithelial neoplasia grade 3 and above; CIN2, cervical intraepithelial neoplasia grade 2; 
CIN1, cervical intraepithelial neoplasia grade 1; HSIL, high-grade squamous intraepithelial lesions 
(incl. atypical cells cannot exclude HSIL); LSIL, low-grade squamous intraepithelial lesions; NILM, 
negative for intraepithelial lesion or malignancy.
TA B L E  2   Worst diagnosis during follow 
up out of women screened in closed 1983 
and 1993 cohorts
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In a sub-analysis, we compared vaccinated and unvaccinated 
women from the 1993 birth cohort, where they had all been offered 
free HPV vaccination, the risk was 44% lower for CIN2+ and 52% 
lower for CIN3+ in vaccinated vs unvaccinated women (RR 0.56; 
95% CI 0.42-0.70 and RR 0.48; 95% CI 0.32-0.63, respectively). The 
risks of CIN1 and NILM were the same in the two groups, reflecting 
that both groups had liquid-based cytology.
4  | DISCUSSION
We found a reduced risk of about 30% for CIN2+ and CIN3+ in the 
1993 birth cohort offered free HPV vaccination as girls compared 
with the 1983 birth cohort not offered free vaccination. The ob-
served decrease seems real, because it coincided with increased di-
agnostic activity. If anything, our data underestimated the effect of 
HPV vaccination. Fewer women in the 1993 cohort than in the 1983 
cohort had HSIL without histology follow up, indicating that possible 
loss to follow up was lower among the 1993 cohort than among the 
1983 cohort. On a national level, 1.7% of all high-grade screening 
samples are lost to follow up.21
It is important to evaluate if real-life effectiveness of HPV vac-
cination is at the level expected from the randomized trials. In the 
FUTURE studies,22 vaccination with at least one dose of the quad-
rivalent HPV vaccine reduced the risk of any CIN2+ by 43% in 
HPV-naive women with normal cytology at the time of vaccination, 
and by 19% in the mixed group of both HPV-naive and non-naive 
women. In our study, 93% of screened women in the 1993 cohort 
had received at least one dose of HPV vaccination, and by far the 
majority were vaccinated at the age of 15 years. According to the 
Danish school health survey from 2010, 37% of 15-year-old girls re-
ported being sexually active,13 and our 1993 cohort, therefore, most 
likely included a mix of HPV-naive and non-naive girls at the time of 
vaccination. Bearing this in mind, the observed decrease of 30% in 
the risk of CIN2+ and CIN3+ was in concordance with the findings 
from the trials, indicating that with a high vaccination coverage, the 
real-life effect of HPV vaccination can approach the effect found in 
the randomized trials.
Our findings are in line with a recent meta-analysis of the real-life 
impact of HPV vaccination showing a 31% reduction for CIN2+ 
among women aged 20-24 years.7 A Danish study comparing women 
vaccinated below age 16 years with unvaccinated women found a 
43% reduction in CIN2+ among those who had reached screening 
age;23 a finding similar to the 44% we found by comparing vaccinated 
with unvaccinated women born in 1993, but clearly higher than the 
26% we found for all screened women. A Swedish study reported a 
64% decrease in CIN2+ in women HPV-vaccinated ≤16 years com-
pared with unvaccinated women. However, this result was based en-
tirely on tests taken before screening age, as only 93 person-years 
and 0 CIN2+ cases were observed in screened women after the age 
of 23 years, when invitation to screening starts in Sweden.24
Scotland started vaccination in 2008 with the bivalent HPV 
vaccine. A Scottish study reported a vaccine effectiveness of 65% 
against CIN2 and of 71% against CIN3+ in birth cohorts offered vac-
cination at age 15 years compared with birth cohorts not offered 
vaccination.25 In the randomized trials, the efficacy for any CIN2+ 
in HPV-naive girls was larger for the bivalent than for the quadriva-
lent HPV vaccine; a difference possibly explained by differences in 
inclusion criteria, HPV-measurement techniques, and/or cross-pro-
tection.26 Notably, comparison of our quadrivalent vaccine data with 
the bivalent vaccine data published from Scotland indicated a similar 
pattern in real life.
It was a strength that we avoided selection bias by comparing 
two birth cohorts; one where HPV vaccination was offered and 
widely accepted, and one where HPV vaccination was not offered 
as part of the immunization program. Selection was limited further 
F I G U R E  2   Relative risks for worst 
cervical histology in screened women 
from the 1993 cohort compared with the 
1983 cohort. CIN, cervical intraepithelial 
neoplasia; NILM, negative for 
intraepithelial lesion or malignancy [Color 
figure can be viewed at wileyonlinelibrary.
com]
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by the fact that cohort members had all reached screening age. The 
use of comprehensive, linkable data from high-quality national reg-
isters was also a strength. By using closed cohorts we mimicked the 
randomized trial design.
Reasons for exclusions were residence in part of Copenhagen 
County, immigration, or emigration. Copenhagen County had a sim-
ilar HPV-vaccination coverage as the rest of Denmark, and this ex-
clusion is unlikely to have affected the generalizability of the results. 
Women living in Denmark only during part of the observation time 
from age 15 to after first invitation to screening had to be excluded, 
because they were not under risk for both exposure/pseudo-expo-
sure and outcome. The proportions of excluded women were similar 
in the two cohorts, 25.5% and 23.2%, although there was a small dif-
ference in the proportion of women excluded because of emigration: 
12% vs 9%, respectively (see Supplementary material, Figure S1). It 
should be noted though that as Denmark started HPV vaccination 
earlier than neighboring countries, we had vaccinated women emi-
grating and unvaccinated women immigrating. HPV-vaccination cov-
erage was therefore higher in our closed 1993 cohort than in women 
born in 1993 and living in Denmark in 2019, 91% vs 78% (statistik.
ssi.dk, accessed 20 March 2019). The reduction in severe cervical 
lesions may be lower in the actual 2019 population than what we 
observed in the closed cohort because of this difference in vaccina-
tion coverage.
The study also had weaknesses. In young women, the shift from 
conventional cytology to mainly SurePath-based liquid-based cytol-
ogy was associated with increased detection of ASCUS+,19,20 with 
more diagnosed CIN cases,27 and a slightly better protection against 
cervical cancer.28 In Denmark, the shift in screening technology took 
place gradually between 2002 and 2015, and technology was not 
recorded in the National Register of Pathology. It was therefore not 
possible to estimate the exact impact of the shift on the effect of 
HPV vaccination, but if anything, the vaccination effect was under-
estimated. The transition may well explain the observed increase in 
normal and low-grade diagnoses from the 1983 cohort to the 1993 
cohort. Perhaps the introduction of HPV triage of ASCUS/LSIL could 
also have contributed to this increase if more women were referred 
to biopsy because of HPV positivity.
It was an underlying assumption that the two birth cohorts aside 
from HPV vaccination had comparable cervical cancer risk profiles; 
an assumption supported by the similarity between the two cohorts 
in geographical distribution, education, age of sexual debut, and 
screening coverage. Changes over time in sexual behavior have been 
reported from, for example, Britain.29 In Denmark the median age of 
sexual debut has been stable at 16 years for the birth cohorts stud-
ied here,14,15 but a recent survey reported a small increase in early 
sexual debut16 and in proportion of women with a high number of 
sexual partners.16 However, as the authors of the survey stated: “the 
relatively small recent changes in women's sexual behavior … are in 
themselves not likely to have strong implications for public health”16 
(p. 183). Daily smoking went down, and as smoking is a risk factor 
for cervical cancer, the effectiveness of HPV vaccination might 
be slightly overestimated. Nonetheless, based on a conservative 
assumption that the relative risk of CIN3+ for smokers vs non-smok-
ers is RR 2,30 the expected relative risk, due to the smaller proportion 
of smokers, would be RR 0.9 (see Supplementary material, Table S2). 
In fact, our finding is still statistically significantly smaller than this 
value (ie, RR 0.68; 95% CI 0.58-0.79) (Table 2).
5  | CONCLUSION
To conclude, we found a c.30% reduction in CIN2+ and CIN3+ after 
introduction of HPV vaccination. Real-life assessment of vaccine 
effectiveness poses problems; not all girls accept the offer of vac-
cination, and the transition to SurePath-based liquid-based cytol-
ogy increased screening sensitivity. As this would tend to diminish a 
potential effect of HPV vaccination, the finding of a 30% reduction 
must be considered to be well in accordance with the 43% found in 
the quadrivalent HPV-vaccination trials.
Many countries may face similar challenges in the study of vac-
cination effects, but real-life knowledge on impact of HPV vaccina-
tion is necessary to optimize future screening of vaccinated birth 
cohorts. Furthermore, the evidence of real-life effectiveness of HPV 
vaccination supports the existence of public HPV-immunization 
programs.
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